(Q52938297)

9 May 2018

title

Wilms' tumour gene 1 (WT1) in human neoplasia. (English)

1 reference

9 May 2018

author name string

Keilholz U

1

1 reference

9 May 2018

Menssen HD

2

1 reference

9 May 2018

Gaiger A

3

1 reference

9 May 2018

Menke A

4

1 reference

9 May 2018

Oji Y

5

1 reference

9 May 2018

Oka Y

6

1 reference

9 May 2018

Scheibenbogen C

7

1 reference

9 May 2018

Stauss H

8

1 reference

9 May 2018

Thiel E

9

1 reference

9 May 2018

Sugiyama H

10

1 reference

9 May 2018

publication date

1 August 2005

1 reference

9 May 2018

published in

Leukemia

1 reference

9 May 2018

volume

19

1 reference

9 May 2018

page(s)

1318-1323

1 reference

9 May 2018

issue

8

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403817

exact match

0 references

cites work

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

WT1 and glomerular function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

WT1 proteins: functions in growth and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Clinical significance of minimal residual disease in childhood acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

PAX8-mediated activation of the wt1 tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

Cancer immunotherapy targeting Wilms' tumor gene WT1 product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403817

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403817

1 reference

9 May 2018

Dimensions Publication ID

0 references

1 reference

9 May 2018